United States· US:0173-0927_ea9e3787-11e0-4516-b419-db3c219a057c
Exdensur
A depemokimab product containing depemokimab, registered in United States by GlaxoSmithKline LLC. The same ATC class is registered in 9 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Depemokimab is registered in 9 of 19 countries.
Countries holding a registration under ATC R03DX12 (depemokimab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 5 of them publish a price we can compare per daily dose
Depemokimab · ATC R03DX12
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DEPEMOKIMAB
- Manufacturer
- GlaxoSmithKline LLC
- Country
- United States (US)
- ATC code
- R03DX12
- ATC class
- Depemokimab
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc110173-0927-42
- ndc110173-0927-61
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Depemokimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumExdensur 100 mgGlaxoSmithKline Trading Services
- CzechiaEXDENSURGlaxoSmithKline Trading Services Limited, Dublin
- SpainEXDENSUR 100 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAGlaxosmithkline Trading Services Limited
- FinlandEXDENSURGlaxoSmithKline Trading Services Limited
- United KingdomExdensur 100mg/1ml solution for injection pre-filled pensGlaxoSmithKline UK Ltd
- IrelandEXDENSUR 100 mg solution for injection in pre-filled penGlaxoSmithKline Trading Services Limited
- IcelandEXDENSURGlaxoSmithKline Trading Services Limited
- Japanデペモキマブ（遺伝子組換え）グラクソ・スミスクライン
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Exdensur
- Liechtenstein · Exdensur
- Norway · Exdensur
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/519ed879-7707-4bcf-afc4-7face761b4b4 GET /v1/drugs/519ed879-7707-4bcf-afc4-7face761b4b4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "100",
"substance": "DEPEMOKIMAB",
"productndc": "0173-0927",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761458",
"marketing_category": "BLA"
}See everything about depemokimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.